We not too long ago compiled an inventory of the 20 Greatest Biotech Shares Underneath $20 to Purchase Now. The tenth inventory on our listing is Legend Biotech Company.
TheFly reported on January 22 that H.C. Wainwright lowered LEGN’s worth goal to $50 from $60 however saved a Purchase score, noting This fall Carvykti gross sales of $555M missed the $582M consensus. They view the current pullback as a shopping for alternative and highlighted Carvykti’s healing potential.
Equally, a day earlier on January 21, TD Cowen downgraded Legend Biotech Company (NASDAQ:LEGN) from Purchase to Maintain and reduce the worth goal to $21 from $62. The agency mentioned Carvykti’s This fall gross sales of $555 million versus the $582 million consensus mirrored vacation seasonality but in addition indicated sluggish demand, which is influenced by toxicity issues and rising competitors. These components have slowed adoption in the neighborhood and restricted uptake even in educational facilities.
Legend Biotech Company (NASDAQ:LEGN) is a world biotechnology firm targeted on growing and commercializing superior cell therapies, particularly CAR‑T therapies for most cancers, like CARVYKTI for a number of myeloma. It collaborates with companions like Johnson & Johnson and builds finish‑to‑finish capabilities from discovery to manufacturing to increase therapeutic influence.
Whereas we acknowledge the potential of LEGN as an funding, we imagine sure AI shares provide better upside potential and carry much less draw back danger. If you happen to’re on the lookout for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 12 Greatest Multibagger Shares to Purchase Heading into 2026 and 7 Greatest Rising Tech Shares to Purchase Now.
Disclosure: None.